BL
REGN icon

Balentine LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Balentine LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,072
Closed -$680K – 210
2025
Q1 		$680K Buy
+1,072
New +$737K 0.03% 92
2024
Q2 		– Sell
-3,278
Closed -$3.16M – 479
2024
Q1 		$3.16M Sell
3,278
-121
-4% -$115K 0.09% 70
2023
Q4 		$2.99M Buy
3,399
+97
+3% +$79.9K 0.1% 75
2023
Q3 		$2.72M Buy
3,302
+45
+1% +$35.4K 0.09% 68
2023
Q2 		$2.34M Buy
3,257
+32
+1% +$24.7K 0.08% 75
2023
Q1 		$2.65M Sell
3,225
-391
-11% -$295K 0.09% 78
2022
Q4 		$2.61M Buy
3,616
+405
+13% +$299K 0.09% 80
2022
Q3 		$2.21M Sell
3,211
-655
-17% -$412K 0.08% 72
2022
Q2 		$2.29M Buy
3,866
+1,587
+70% +$1.03M 0.08% 96
2022
Q1 		$1.59M Buy
2,279
+1,652
+263% +$1.05M 0.05% 105
2021
Q4 		$396K Buy
627
+44
+8% +$27.1K 0.01% 202
2021
Q3 		$353K Buy
+583
New +$362K 0.01% 161
2020
Q3 		– Sell
-99
Closed -$62K – 693
2020
Q2 		$62K Buy
99
+9
+10% +$5.11K ﹤0.01% 210
2020
Q1 		$44K Buy
90
+86
+2,150% +$35.5K ﹤0.01% 191
2019
Q4 		$2K Hold
4
– – ﹤0.01% 543
2019
Q3 		$1K Sell
4
-3
-43% -$888 ﹤0.01% 713
2019
Q2 		$2K Buy
+7
New +$2.33K ﹤0.01% 645
2018
Q1 		– Sell
-31
Closed -$12K – 420
2017
Q4 		$12K Sell
31
-27
-47% -$10.9K ﹤0.01% 448
2017
Q3 		$26K Hold
58
– – ﹤0.01% 358
2017
Q2 		$28K Hold
58
– – ﹤0.01% 324
2017
Q1 		$22K Buy
58
+31
+115% +$11.5K ﹤0.01% 331
2016
Q4 		$10K Hold
27
– – ﹤0.01% 409
2016
Q3 		$11K Hold
27
– – ﹤0.01% 350
2016
Q2 		$9K Buy
+27
New +$10.4K ﹤0.01% 365
2016
Q1 		– Sell
-74
Closed -$40K – 383
2015
Q4 		$40K Buy
+74
New +$40.1K 0.01% 175

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Balentine LLC's REGN Position: Q2 2025 in Review

Balentine LLC sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 1,072 shares — an estimated $680K sold.

Balentine LLC first reported a position in REGN in Q4 2015 and held it in 25 quarters. The position peaked at $3.16M in Q1 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Balentine LLC reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Balentine LLC sold 1,072 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $680K.
  • Balentine LLC first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 25 quarters.
  • Balentine LLC's Regeneron Pharmaceuticals position peaked at $3.16M in Q1 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Balentine LLC's 13F filing for Q2 2025, filed 4 Aug 2025.